

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian yang berjudul Studi Efektivitas dan Efek Samping Terapi Kombinasi Oseltamivir dan Klorokuin pada Pasien COVID-19 di Instalasi Rawat Inap Rumah Sakit Bhayangkara Surabaya periode Maret – Desember 2020 diperoleh kesimpulan sebagai berikut :

- a. Regimen pemberian dosis klorokuin dengan oseltamivir di instalasi rawat inap Rumah Sakit Bhayangkara yaitu oseltamivir (2x75mg) dan klorokuin (2x500mg) dengan adanya penurunan dosis klorokuin menjadi (2x250mg), oseltamivir (2x75mg) dengan klorokuin (2x500mg), dan oseltamivir (2x75mg) dengan klorokuin (2x250mg).
- b. Kejadian efek samping prolonged QT hanya terjadi pada 1 pasien dan secara umum terapi kombinasi oseltamivir dan klorokuin tidak menyebabkan *prolonged QT*.
- c. Hasil pemeriksaan fungsi hati normal, jadi terapi kombinasi oseltamivir dengan klorokuin tidak menyebabkan kerusakan hati.
- d. Hasil pemeriksaan fungsi ginjal menunjukkan 17% pasien mengalami kenaikan serum kreatinin.

5.2 Saran

- a. Diperlukan penelitian lebih lanjut dengan menggunakan metode prospektif dalam mengamati permasalahan terapi, efektivitas obat dengan jumlah sampel yang lebih besar dan rekam medis yang lebih lengkap.
- b. Diharapkan untuk seluruh tenaga medis yang terkait dengan penanganan pasien COVID-19 dapat memberikan upaya pelayanan kesehatan yang maksimal sehingga dapat meningkatkan kualitas hidup

pasien.

DAFTAR PUSTAKA

- Akhtar, M., D. 2020, COVID-19 inhibitors: A prospective therapeutics, *Bioorganic Chemistry*, 1-9.
- Badan POM. 2020, Langkah Strategis Badan POM Dalam Penanganan Obat COVID-19, Jakarta : Badan Pengawas Obat dan Makanan Republik Indonesia.
- Cai, H. 2020, Sex difference and smoking predisposition in patients with COVID-19, *The Lancet Respiratory Medicine*, **8(4)**: e20.
- Cascella, M., et al. 2020, Features Evaluation and Treatment Coronavirus (COVID-19), *StatPearls NCBI Bookshelf*, 1-16.
- Cai, Q., Huang, D., Yu, H., Zhu, Z., Xia, Z., Su, Y., Li, Z., Zhou, G., Gou, J., QU, J., Sun, Y., Liu, Y., He, Q., Chen, Liu, L., and Xu, L. 2020, COVID-19: abnormal liver function tests, *Journal of hepatology*, **73(3)**: 566-574.
- Chai, X., Hu, L., Zhang, Y., Han, W., Lu, Z., Ke, A., and Lan, F. 2020, Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection, *biorxiv*.
- Chan-Yeung, M., and Rui-Heng, X. 2003, SARS: epidemiology. *Respirology*, **8**: S9-S14.
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., and Zhang, L. 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, *The lancet*, **395(10223)**: 507-513.
- Chen, Y., Liu, Q., and Guo, D. 2020, Emerging Coronaviruses: Genome Structure, Replication, and Pathogenesis, *Journal of Medical Virology*, 92: 418-423.
- Chiba, S. 2020, Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. *Wiener klinische*

Wochenschrift, 1-6.

- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). (2020). Identifier NCT04303299, Various combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID-19: A Randomized Control Trial (THDMS-COVID19)
- Davies, B.E.2010, Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations, *Journal of antimicrobial chemotherapy*, **65(2)**: ii5-ii10.
- Diaz, J. H. 2020, Hypothesis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers May Increase The Risk of Severe COVID-19, *Journal of Travel Medicine*, **27(3)**: 1–2.
- Falcao, M. B., et al. 2020, Case report: hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19, *The American journal of tropical medicine and hygiene*, **102(6)**: 1214-1216.
- Fang, S., Qi, L., Zhou, N., and Li, C. 2018, Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. *Medicine*, **97(38)**.
- Fatullah, I. 2017. ‘Hubungan Prolongasi Interval QTc dengan Kejadian Kardiovaskular Mayor selama Perawatan pada Pasien Infark Miokard Akut Non levasi Segmen ST di RSUP Dr. M. Djamil Padang, *Skripsi*, Program Studi Pendidikan Profesi Dokter Spesialis-1, Padang.
- Fehrl, A.R., and Perlman, S. 2015, ‘Coronaviruses: An Overview of Their Replication and Pathogenesis’, in Maier, H.J., Bickerton, E. and Britten, P., *Coronaviruses Methods and Protocols*, Humana Press, UK, pp 1-23.
- Gao, J., Tian X. and Yang, X. 2020, Breakthrough: Chloroquine

Phosphate has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies, *BioScience Trends*, **14(1)**: 72-73.

Gautret, P., et al. 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, *International journal of antimicrobial agents*, **56(1)**: 105949.

Gunawan, S.G. 2016. Farmakologi dan Terapi Edisi 6, Badan Penerbit FKUI, Jakarta.

Haitao, T., Vermunt, J., Abeykoon, J., Ghamrawi, R., Gunaratne, M., Jayachandran, M., and Garovic, V. 2020, COVID-19 and sex differences: mechanisms and biomarkers, In Mayo Clinic Proceeding, *Elsevier*.

Hashem, A.M., Alghamdi, B.S., Algaissi, A.A., Alshehri, F.S., Bukhari, A., Alfaleh, M.A., and Memish, Z.A. 2020, Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review, *Travel Medicine and Infectious Disease*, 101735.

Kementerian Kesehatan Republik Indonesia, 2020, Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19), Jakarta : Kementerian Kesehatan Republik Indonesia dan Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P).

Kementerian Kesehatan Republik Indonesia, 2011, Pedoman Interpretasi Data Klinik, Jakarta.

Li, X., et al. 2020. Molecular Immune Pathogenesis and Diagnosis of COVID-19, **Journal of Pharmaceutical Analysis**, **10**: 102-108.

Mohamed, J., Nafizah, A. N., Zariyantey, A. H., and Budin, S. 2016, Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation, **Sultan Qaboos University**

Medical Journal, 16(2): e132.

Mahmoudi, J., Sadigh-Eteghad, S., Salehi-Pourmehr, H., Gharekhani, A., and Ziaee, M. 2020, Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients, *Advanced Pharmaceutical Bulletin*, **11(1)**: 6-7.

Marmor, M.F., et al. 2016, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision), *Ophthalmology*, **123**: 1386–1394.

Novita, N.F., & Destiany, D.P.2020, Interaksi Obat terhadap Perpanjangan Interval QT, *Farmaka*, **18(1)**: 110-118.

PERDAFKI. 2020, Kajian Farmakoterapi Pengobatan COVID-19, Jakarta : Perhimpunan Dokter Spesialis Farmakologi Klinik Indonesia.

PERKI. 2020, Panduan Diagnosis dan Tatalaksana Penyakit Kardiovaskular pada Pandemi COVID-19, Jakarta : Perhimpunan Dokter Spesialis Kardiovaskular Indonesia.

PDPI. 2020, Pneumonia COVID-19 Diagnosis dan Penatalaksanaan di Indonesia, Jakarta : Perhimpunan Dokter Paru Indonesia.

Rosenthal, P.J. 2017, ‘Antiprotozoal Drugs’, in Katzung, B.G., Basic & Clinical Pharmacology, 14th ed., McGraw-Hill Education, San Francisco, pp 917-937.

Rosida, A. 2016, Pemeriksaan laboratorium penyakit hati, *Berkala Kedokteran Unlam*, **12(1)**: 123-131.

Russo, F., et al. 2020, Epidemiology and public health response in early phase of COVID-19 pandemic, Veneto Region, Italy, 21 February to 2 April 2020, *Eurosurveillance*, **25(47)**: 2000548.

Satgas COVID-19 Indonesia, Peta Sebaran (internet):diakses pada 3 Mei 2020,<https://covid19.go.id/peta-sebaran-covid19>.

Sanders, J. M., et al. 2020, Pharmacologic treatments for coronavirus

- disease 2019 (COVID-19): a review, *Jama*, **323(18)**: 1824-1836.
- Sarwono, J. 2006, Metode Penelitian Kuantitatif dan Kualitatif, Graha Ilmu, Yogyakarta.
- Savarino, A., et al. 2003, Effects of chloroquine on viral infections: an old drug against today's diseases, *The Lancet infectious diseases*, **3(11)**: 722-727.
- Schrezenmeier, E., and Dorner, T. 2020, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, *Nature Reviews Rheumatology*, 1-12.
- Shah, K.B., et al. 2019, Oseltamivir induced sinus bradycardia: an area of potential concern, *International Journal of Basic & Clinical Pharmacology*, **8(1)**: 162.
- Smith, T., et al. 2020, COVID-19 Drug Therapy, *Clinical Drug Information*, 1-29.
- Suman, R. K., Mohanty, I. R., andDeshmukh, Y. A. 2014, The concepts of drug utilization study, *World Journal of Pharmaceutical and science*, **3**:352-363.
- Susilo, A.,et al.2020, Coronavirus Disease 2019: Tinjauan Literatur Terkini, *Jurnal Penyakit Dalam Indonesia*, **7(1)**: 45-67.
- Thahir, S., Hasanuddin, A., & Hardianti, D. (2019). Gambaran Kadar Serum Glutamate Pyruvat Transminase (SGPT) Dan Glutamate Pyruvat Transminase (SGPT) Diabetes Melitus Di RSUD Syekh Yusuf Kab. Gowa, *Jurnal Media Laboran*, **9(2)**: 23-28.
- Tjay, T.H., and Rahardja, K. 2015, Obat-obat Penting Khusus, Penggunaan dan Efek-efek Samping, Edisi Ketujuh, PT. Elex Media Komputindo, Jakarta.
- Wang, B., Guo, H., Ling, L., Ji, J., Niu, J., & Gu, Y. 2020, The

chronic adverse effect of chloroquine on kidney in rats through an autophagy dependent and independent pathways, *Nephron*, **144(2)**: 96-108.

Wang, M., et al.2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, *Cell Research*, **30(3)**:269–271.

Wang, Z. (eds). 2020. A Handbook of 2019-nCoV Pneumonia Control and Prevention, *Hubei Science and Technology Press*, 4-108.

World Health Organization. Global surveillance for human infection with novel Coronavirus (2019-nCoV). [Internet]. 2020 [cited 20 March 2020]Available from:[https://www.who.int/publications/i/item/global-surveillance-for-human-infection-with-novel-coronavirus-\(COVID-19\)](https://www.who.int/publications/i/item/global-surveillance-for-human-infection-with-novel-coronavirus-(COVID-19))

Zhang, H., et al. 2020, Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target, *Intensive Care Med*, **46**: 586–590.